Table 3. Univariate and multivariate analysis assessing the OR of treatment termination associated with clinical variables and body composition markers in patients with GC.
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P-value | OR | 95% CI | P-value | ||
| Age (yr) | |||||||
| <65 | 1.00 | 0.920 | 1.00 | 0.308 | |||
| ≥65 | 1.06 | 0.30–3.81 | 0.44 | 0.08–2.08 | |||
| Sex | Excluded | ||||||
| Male | 1.00 | 0.700 | |||||
| Female | 1.27 | 0.34–4.50 | |||||
| Tumor site | |||||||
| Body | 1.00 | 0.420 | |||||
| Antrum/GEJ | 1.63 | 0.49–5.61 | |||||
| Stage | Excluded | ||||||
| II | 1.00 | 0.260 | |||||
| III | 0.33 | 0.04–2.23 | |||||
| Histology type | Excluded | ||||||
| Intestinal | 1.00 | 0.640 | |||||
| Diffuse/mixed | 1.36 | 0.34–5.24 | |||||
| SMA | 0.98 | 0.96–1.00 | 0.250 | Excluded | |||
| VFA | 1.00 | 0.99–1.01 | 0.120 | Excluded | |||
| SFA | 1.00 | 0.99–1.01 | 0.280 | Excluded | |||
| MA (HU) | |||||||
| <35 | 1.00 | 0.040 | 1.00 | 0.040 | |||
| ≥35 | 0.27 | 0.06–0.95 | 0.20 | 0.33–0.95 | |||
| Sarcopenia | |||||||
| No | 1.00 | 0.030 | 1.00 | 0.050 | |||
| Yes | 4.55 | 1.13–20.70 | 4.23 | 0.98–20.80 | |||
| Sarcopenic obesity | Not included* | ||||||
| No | 1.00 | ||||||
| Yes | 106,362,030.9 | 2.81×10−72-NA | <0.001 | ||||
OR = odds ratio; GC = gastric cancer; CI = confidence interval; GEJ = gastroesophageal junction; SMA = skeletal muscle area; VFA = visceral fat area; SFA = subcutaneous fat area; MA = muscle radiation attenuation; HU = Hounsfield unit.
*All patients with sarcopenic obesity experienced treatment termination, and for that reason a high OR was obtained, and the upper 95% CI limit was not possible to calculate. This variable was not included in the final model to avoid error in parameter estimation.